This webinar will give an overview of CMA interventionism, in collaboration with the American Bar Association (ABA). 

Thermo Fisher Scientific/Roper Technologies, Illumina/Pacific Biosciences, Roche/Spark, Sabre/Farelogix – just four of the global deals over which the UK’s Competition & Markets Authority has recently asserted merger control jurisdiction and, in the case of three of them, either blocked or caused abandonment.

To many international eyes, the CMA has been adopting an aggressive approach to jurisdiction and asserting itself by sustaining concerns about international deals in circumstances where other antitrust agencies and courts have not shared those concerns. Is the CMA the new global antitrust policeman when it comes to merger control and is this a taste of things to come in the Brexit era?  Have its decisions, on jurisdiction and substance, been justified, or is it overextending its reach?

This discussion, co-hosted by the ABA Antitrust Section’s Mergers & Acquisition Committee and the Competition Section of the Law Society of England & Wales, brings together leading practitioners from both sides of the Atlantic to explore and perhaps explain the CMA’s recent approach to merger control. 

This webinar covers:

  • recent CMA merger cases (including Thermo Fisher Scientific/Roper Technologies, Illumina/Pacific Biosciences, Roche/Spark, Sabre/Farelogix)
  • discussion on the scope of the CMA’s jurisdiction over international transactions
  • the view from the USA of the CMA’s recent decisional practice

By attending this webinar, you will gain:

  • Insight into recent, contentious, CMA merger control proceedings
  • An understanding of the approach the CMA is taking to global deals and how to factor this into future transactional risk assessments

For further details on the ABA Antitrust section Mergers & Acquistion committee, please visit their website. The event will begin at 5pm GMT on 17 June. 

SRA Competence



Miranda Cole – Partner at Covington & Burling LLP 

More speakers will be confirmed shortly.